Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET
Lantern Pharma (NASDAQ: LTRN), an AI-driven cancer therapy development company, will host its third quarter 2024 operating and financial results webcast on Thursday, November 7, at 4:30 p.m. ET. CEO Panna Sharma and management will discuss Q3 2024 results ending September 30, provide guidance on upcoming milestones, clinical trials, and developments of their proprietary RADR® AI and machine learning platform. A replay will be available on the company's investor relations website after the call.
Lantern Pharma (NASDAQ: LTRN), un'azienda dedicata allo sviluppo di terapie oncologiche tramite intelligenza artificiale, ospiterà il suo webcast sui risultati operativi e finanziari del terzo trimestre 2024 giovedì 7 novembre alle 16:30 ET. Il CEO Panna Sharma e il management discuteranno dei risultati del Q3 2024 chiuso il 30 settembre, forniranno indicazioni sui prossimi traguardi, studi clinici e sviluppi della loro piattaforma proprietaria RADR® AI e machine learning. Una registrazione sarà disponibile sul sito web delle relazioni con gli investitori dell'azienda dopo la chiamata.
Lantern Pharma (NASDAQ: LTRN), una empresa dedicada al desarrollo de terapias contra el cáncer impulsadas por inteligencia artificial, llevará a cabo su webcast de resultados operativos y financieros del tercer trimestre de 2024 el jueves 7 de noviembre a las 4:30 p.m. ET. La CEO Panna Sharma y la dirección discutirán los resultados del Q3 2024 que finaliza el 30 de septiembre, proporcionarán orientación sobre los próximos hitos, ensayos clínicos y desarrollos de su plataforma propietaria RADR® AI y machine learning. Una repetición estará disponible en el sitio web de relaciones con inversores de la compañía después de la llamada.
랜턴 파르마 (NASDAQ: LTRN), AI 기반 암 치료 개발 회사는 2024년 3분기 운영 및 재무 결과 웹캐스트를 11월 7일 목요일 오후 4시 30분 ET에 진행합니다. CEO 판나 샤르마와 경영진은 9월 30일 종료된 2024년 3분기 결과를 논의하고, 다가오는 이정표, 임상 시험 및 그들의 독자적인 RADR® AI 및 머신러닝 플랫폼의 개발에 대한 안내를 제공합니다. 호출 후 회사의 투자자 관계 웹사이트에서 재생이 가능합니다.
Lantern Pharma (NASDAQ: LTRN), une entreprise de développement de thérapies contre le cancer utilisant l'intelligence artificielle, organisera son webcast sur les résultats opérationnels et financiers du troisième trimestre 2024 le jeudi 7 novembre à 16h30 ET. Le CEO Panna Sharma et la direction discuteront des résultats du T3 2024 se terminant le 30 septembre, fourniront des conseils sur les prochaines étapes clés, les essais cliniques et les développements de leur plateforme propriétaire RADR® AI et machine learning. Un enregistrement sera disponible sur le site web des relations avec les investisseurs de l'entreprise après l'appel.
Lantern Pharma (NASDAQ: LTRN), ein auf KI basierendes Unternehmen zur Entwicklung von Krebstherapien, wird am Donnerstag, den 7. November, um 16:30 Uhr ET ein Webcast zu den operative und finanziellen Ergebnissen des dritten Quartals 2024 veranstalten. CEO Panna Sharma und das Management werden die Ergebnisse des Q3 2024, das am 30. September endete, besprechen und Hinweise zu bevorstehenden Meilensteinen, klinischen Studien und Entwicklungen ihrer proprietären RADR® AI- und Machine Learning-Plattform geben. Eine Wiederholung wird nach dem Gespräch auf der Website der Investor Relations des Unternehmens verfügbar sein.
- None.
- None.
- Webcast to be held Thursday, November 7th, 4:30 p.m. ET, register for the webcast here, or at the link provided below.
Management intends to discuss the operating and financial results for the third quarter ended September 30, 2024 and provide guidance on upcoming milestones, clinical trials and developments of the AI platform, RADR®. Panna Sharma, President and Chief Executive Officer of Lantern Pharma, will lead the call and will be joined by other members of the management team.
To register for the webinar, please sign up at the Zoom webcast link provided: Lantern Pharma Q3, 2024 earnings Zoom webcast registration. A replay of the earnings call webcast will be available after the call on the investor relations section of the Company's website: ir.lanternpharma.com.
About Lantern Pharma
Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 100 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately
Our lead development programs include a Phase 2 clinical program and multiple Phase 1 clinical trials. We have also established a wholly-owned subsidiary, Starlight Therapeutics, to focus exclusively on the clinical execution of our promising therapies for CNS and brain cancers, many of which have no effective treatment options. Our AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over
Additional information:
Website: www.lanternpharma.com
LinkedIn: https://www.linkedin.com/company/lanternpharma/
X: @lanternpharma
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "model," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that our research and the research of our collaborators may not be successful, (ii) the risk that observations in preclinical studies and early or preliminary observations in clinical studies do not ensure that later observations, studies and development will be consistent or successful, (iii) the risk that we may not be successful in licensing potential candidates or in completing potential partnerships and collaborations, (iv) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (v) the risk that no drug product based on our proprietary RADR® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (vi) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on March 18, 2024. You may access our Annual Report on Form 10-K for the year ended December 31, 2023 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241031234949/en/
Investor Relations Contact:
Investor Relations at Lantern Pharma
ir@lanternpharma.com
Source: Lantern Pharma Inc.
FAQ
When will Lantern Pharma (LTRN) report Q3 2024 earnings?
What will be discussed in Lantern Pharma's (LTRN) Q3 2024 earnings call?